Malignant osteopetrosis (MOP) is an autosomal recessive disease in which osteoclast dysfunction results in excessive bone deposition and early infant death. Thirteen children suffering from MOP from four related families all belonging to one Bedouin tribe, were studied. The disease was diagnosed as early as at a few days postnatal to 5 months. Nine children underwent BMT, four of whom are still alive; one is blind and two have markedly reduced vision. Four children who did not undergo BMT died between 4 and 6 months of age. Recently, the gene for MOP has been mapped for this Bedouin tribe allowing prenatal diagnosis. Seven pregnancies were subsequently prenatally diagnosed and two fetuses were found to be affected. Pregnancy was electively terminated in one case. In the other case the parents refused and after establishing the diagnosis, the newborn was transplanted at the age of 7 days. Bone Marrow Transplantation (2001) 27, 129-132.
Osteopetrosis, a heterogeneous group of inherited diseases of the skeleton, is known in three clinical variants namely: (1) infantile or malignant osteopetrosis, an autosomal recessive disorder; (2) the autosomal dominant type that clinically presents during early adolescence and is a more benign form;
1,2 and (3) a malfunction of the osteoclasts combined with renal tubular acidosis due to carbonic anhydrase II deficiency. 3, 4 Malignant osteopetrosis (MOP) is characterized by a lack of osteoclastic function which prevents bone re-absorption and leads to excessive bone mineralization and bone encroachment on the cranial cavity, foramina and marrow space. Afflicted patients die in early childhood. [5] [6] [7] [8] In a group of 13 Bedouin patients, all children of consanguineous parents, the gene for MOP was recently localized to chromosome 11q12-13 by linkage analysis. 9 In this report, we present the clinical phenotype and disease course of these patients with infantile osteopetrosis, who were all diagnosed at our center.
Patients and methods
We present a retrospective study of 13 infants (eight females and 5 males) diagnosed with MOP at a mean age of 41 days (range 1 day to five months). All the patients belong to four interrelated Bedouin families living in the Negev region of Israel and all of them are children of consanguineous parents. In four infants, the diagnosis was established soon after birth; in three, based on a family history of a previously affected sibling, and in the fourth case, based on prenatal diagnosis. However, the parents declined termination of pregnancy.
Initial symptoms
All patients were small for their gestational age with a birth weight percentile smaller than that of their head circumference. Bulging fontanelle and hepatosplenomegaly were the presenting clinical symptoms in 12 of the 13 infants (Table 1) . In two patients, lumbar punctures were carried out and normal cerebro-fluid pressure was measured. CTs of the brain were performed on all infants; however, no signs of hydrocephalus or increased intracranial pressure were detected. In three infants, ocular involvement and optic atrophy were diagnosed at the age of 2 and 3 months. One infant presented with hypocalcemic seizures at the age of 10 days.
Laboratory data at diagnosis
Peripheral blood smears of all patients, including those diagnosed soon after birth, showed a leukemoid reaction. Two children were referred to our center with the diagnosis of congenital leukemia. Patient-specific data are listed in Table 1 . Thrombocytopenia, less than 150 × 10 9 /l was detected in 10 patients. Anemia, with a hemoglobin level less than 9 g% (range 8.9-6.1 g%) was found in four patients at the age of 12 days to 4 months. In four patients, the serum calcium levels (less than 7 mg) (normal range 8.4-10.4 mg/dl) were identified. One patient with hypocalcemic seizures had a serum calcium level of 5.2 mg/dl. Serum parathyroid hormone levels was determined in eight patients, all of whom had increased levels. Plasma lactate dehydrogenase, bone alkaline phosphase and 1,25 vitamin D, were elevated in all patients. All patients, including the four cases diagnosed at birth, had radiological evidence of markedly increased bone density. A bone fracture was observed in one patient after birth.
Prenatal diagnosis
Using linked micro-satellite markers in the region of chromosome 11q12-13, 9 prenatal diagnoses were performed for seven pregnancies with a 25% risk for fetuses affected with MOP. Prenatal diagnosis was performed at 10-16 weeks of CAM = campath-1G; Cyclo = cyclophosphamide; ARDS = acute respiratory distress syndrome; Bu = busulfan; CGVHD = chronic graft-versus-host disease; AH = alveolar hemorrhage; TT = thiotepa; ATA = anti-thymocyte globulin.
gestation age by either chorionic villous biopsy or amniocentesis.
Bone marrow transplantation
Nine of 13 patients underwent BMT at the age of 7 days to 6 months (mean 50 days). One of the infants diagnosed at birth was transplanted at the age of 7 days. Eight patients received HLA-A, B, DR-matched sibling donor marrow and one was transplanted with bone marrow from his mother (5/6 HLA-matched to rejection vector). The preparative regimen is shown in Table 2 . All patients received cyclosporin A as GVHD prophylaxis. Seven patients had an abnormal visual response with various degrees of clinical visual impairment at the time of BMT. Of the four patients who were not transplanted (three due to the lack of a compatible donor and one due to parental refusal) three died of infection and bone marrow failure and one of intracranial bleeding at the ages of 4 to 6 months.
Results

Bone marrow transplantation
Seven of nine BMT patients engrafted at a median of 24 days (range 15-56 days for ANC of more than 1000/dl). One patient engrafted partially (200/dl ANC) and died of pulmonary haemorrhage. One patient died of ARDS without engrafting, two patients died of alveolar hemorrhage and two patients of severe ARDS. Four patients are alive, of whom three are 2.5-7 years post BMT; all four are full donor chimeras. Patient characteristics of the surviving children are listed in Table 2 . All patients are failing to thrive with their height and weight below the 5th percentile. They all have impaired vision with two patients (6 months and 2.5 years post BMT) being legally blind, although at the time of transplantation they had normal vision. A third patient has a decrease in visual acuity with mild chronic GVHD and bilateral cataracts. Normalization of bone resorption was evident by tabulation of long bones demonstrated by X-ray analysis. The intellectual development of all patients is normal. None of the patients developed acute GVHD.
Prenatal diagnosis
Seven fetuses (five males and two females) were prenatally tested for MOP. Five were found to be unaffected and they were born at term with no evidence of the disease, whereas two fetuses were diagnosed with MOP. One pregnancy was electively terminated, whereas in the second case, termination was refused on religious grounds. This newborn's MOP was verified soon after birth and he was subsequently transplanted at the age of 7 days. Currently, 6 months post BMT he has a normal blood count and is a 100% donor chimera. However, he is severely visually impaired.
Discussion
Osteopetrosis is a rare congenital autosomal recessive disorder characterized by the development of abnormally dense bones, anemia and progressive deafness and blindness.
Although the clinical course of MOP is rapidly progressive and in most of the affected infants, lethal at a very young age, some may survive for more than 6 years and a minority of patients may live into their second or third decade. [5] [6] [7] Clinical presentation and disease development vary among patients. In our group of patients, symptoms and signs of the disease appeared very shortly after birth included bulging fontanelles and evidence of extramedullary hematopoiesis. Visual impairment and other neurological symptoms have been reported in most MOP patients in the first 3 months of life due to cranial nerve encroachment or primary retinal degeneration and neurodegeneration, [10] [11] [12] which have persisted and even proceeded after BMT. 13 All our surviving patients also have visual impairment. One girl who had no pre-BMT ophthalmological problems, developed severe visual impairment due to optic nerve compression 1 year post BMT. This process proceeded despite 100% donor stem cell engraftment.
MOP has been treated with parathyroid hormone, highdose calcitriol and prednisone and recently with recombinant human interferon gamma. However, the only curative approach known today for osteopetrosis is allogenic BMT. [13] [14] [15] [16] [17] [18] Only four of the nine patients who underwent BMT in our group survived although eight of the nine patients achieved primary engraftment. According to our experience and as previously described, the major transplant-related complications are interstitial pneumonitis and alveolar hemorrhage, leading to respiratory failure and death. 4, 6, 13 These complications could well be attributed to
Bone Marrow Transplantation hypersensitivity to busulfan administered as part of the preparative regimen for BMT. However, we cannot exclude the possibility that, due to extramedullary hematopoiesis, macrophages and granulocytes are displaced. Following intensive chemotherapy these cells undergo apoptosis, releasing cytokines at high levels. Although osteopetrosis is genetically heterogeneous and there is probably more than one genetic locus and certainly more than one mutation even for the malignant form, it is likely that all our patients, being homozygotes by descent from a common ancestor, bear the same gene defect. This allows a fairly accurate prenatal diagnosis even at the present stage where only linkage data are available. The recent cloning of the mouse osteopetrosis gene 18 holds promise for the future identification of the human homologue. Since optimal therapy for MOP is available today (including BMT, even at a very early stage of the disease), cloning of the human MOP gene may eventually lead to future gene therapy. For the present, however, prenatal stem cell transplantation may become a more realistic treatment option for this disease.
